Semaglutide linked to lower risk of heart death in trial review

A single medicine across varied health issues

Can a medicine first made for high blood sugar also protect the heart? Semaglutide is widely known for cutting body weight and managing diabetes. In a fresh review, researchers asked if semaglutide heart protection could lower the risk of fatal heart events across diverse patient groups.

Gathering data from 38,000 adults

To find out, researchers pulled together seven clinical trials that included 38,412 adults. These volunteers had diverse health problems, from kidney disease and high weight to heart failure with preserved ejection fraction. In that heart state, the muscle pumps normally but remains too stiff to fill with blood properly. By pooling these trials in a meta-analysis, the team looked for wide patterns that single trials might miss.

This pooling method matters because it gives far more statistical power than any single trial on its own. The combined results showed a clear pattern. People given semaglutide had a 17% lower relative risk of cardiovascular death than people on a dummy treatment, called a placebo. The calculated hazard ratio was 0.83, meaning the treated group had fewer fatal heart events over time.

This link did not depend on baseline blood sugar, body weight, age, or sex. It held up whether patients swallowed a daily tablet or took a weekly shot under the skin. It also remained steady if people were already taking an SGLT2i, another class of drugs used for kidneys and hearts.

What questions remain open

Think of this protection like a water sealant applied to garden wood. Whether you spray it or paint it on, the coat helps keep out damp. Yet human bodies are far more complex than timber, and the step-by-step biological paths remain unclear. The length of each trial explained most of the variation in the outcomes. Longer studies will help show how trial duration shapes these results over time.